

The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited

李 氏 大 藥 廠 控 股 有 限 公 司*

(incorporated in the Cayman Islands with limited liability)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “Board”) of Lee's Pharmaceutical Holdings Limited (the “Company”) is pleased to announce that Dr. Li Xiaoyi (“Dr. Li”) will be appointed as an executive director of the Company with effect from 1 September 2003.

Dr. Li, aged 41, is the Chief Technical Officer of the Company and has been working with the Group for more than 9 years. Dr. Li holds a Ph.D. of Pharmacology from the University of Illinois in Chicago and was a postdoctoral fellow with Warner-Lambert, a major pharmaceutical company in the United States of America.

The Company would like to express its warmest welcome to Dr. Li for his joining the Board and deeply believes that his extensive expertise in biopharmaceutical field will be beneficial to the Company in its overall business development.

By Order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 27 August 2003

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Company Announcement” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.leespharm.com.

* For identification purpose only